Omeros Corporation June 1st
Omeros Corporation (OMER) has a PDUFA date of June 1 for its drug OMS 302 designed to treat occular inflammation in patients undergoing intraocular lens replacement surgery. In terms of the potential for an increase in share price potential it appears as though this stock still has some room to run in the next week heading into its PDUFA date. However, it is important to note that investors need to be careful as the date June 1 is a Sunday. This means that the FDA could do two different things, it could release the decision on Friday the 30th, or it could release its decision on Monday June 2nd. While I view the Monday as being more likely, it should be noted for investors that there is a chance that the FDA would come out with its decision early.
OMS 302 is very important to the future of Omeros, and as such I believe that the stock still has some room to run. This drug would be Omeros' first approved drug, and as such if approved it would serve as a sort of validating drug for Omeros (proving that it can see a product through to approval). However, it is even more important for Omeros given its sales potential. Some analysts have the sales for the drug pegged in the $500 million range. While I would not be this optimistic about the peak sales of the drug, I do believe that the drug will provide substantial revenue for Omeros going forward and at least for the next few years it would be one of the primary drivers of growth in Omeros' stock price moving forward. In regards to the Phase III trials, they met all of their primary endpoints and did not show any significant safety issues, which means that I am expecting approval of the drug. This drug is very important to Omeros and as such we can expect to see more of a runup heading into the PDUFA decision in approximately a week.
This per Alexander Maxwell (Seeking Alpha)
My guess is we see a 500m market cap tomorrow 6/2/14.
All in my opinion of course.
